You can count Seres Health among the wave of biotech companies starting the year with a big new round of venture cash. The Cambridge, MA-based biotech--which has set out to make its reputation in the trendy new microbiome space--said today that it raised $65 million from Nestle Health Science.
South San Francisco oncology specialist CytomX raised a $20 million C round to advance its in-house pipeline of novel cancer treatments, with partner Pfizer pouring in the lion's share of the new cash.
The Third Rock-launched Global Blood Therapeutics has rounded up $48 million to push into the clinic with an experimental therapy for sickle cell disease and set the stage for an IPO later this year--once they have proof-of-concept data for their drug in hand.
Yesterday's news that Moderna raised $450 million on the back of its preclinical R&D work--on top of the $500 million it already banked--stood out as the biggest new venture round recorded for an early-stage biotech like this. But it's still just a piece of the money that's been flowing into biotech over the past year--and a likely harbinger of more good things to come in 2015.
Superlatively well-funded biotech Moderna Therapeutics has raised another $450 million in venture cash, planning to staff up and buckle down on a slew of preclinical candidates that promises to transform patients' cells into drug factories.
Berkeley, CA's Aduro Biotech pulled in $51.4 million in Series D cash, fattening its wallet as the company works through mid-stage trials with a promising immuno-oncology pairing.
In early 2013, Roche signed a $595 million deal with Israel's Chiasma with eyes on its promising treatment for the hormone disorder acromegaly. But the Swiss drugmaker got cold feet over the summer, and now Chiasma is picking up the pieces, raising cash in hopes of submitting its drug to regulators this year.
Billions of dollars in new biotech investments are being made, R&D is being globalized more than ever before and new technologies and drug classes are moving fast through the clinic. FierceBiotech assesses what we believe are the 5 top trends to watch in the year ahead.
Startup Padlock Therapeutics has a novel approach to autoimmune disease that could reduce the need for immunosuppressants, and the biotech has $23 million in fresh cash to explore the idea.
After shunning public attention for more than a year, cancer immunotherapy startup Flexus Biosciences is ready for the limelight now that it is headed toward the clinic, has banked its first two venture rounds totaling $38 million and boasts impressive management, board and advisory rosters.